Skip to main
TEVA

Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Teva Pharmaceutical (TEVA) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Teva Pharmaceutical Indus is expected to experience strong growth in the coming years, with a focus on innovation and strategic acquisitions. The company's diverse portfolio and pipeline, including promising drugs such as TEV-53408 and Ecopipam, make it well-positioned for success. Teva's expertise in injectable products and plans for internal antibody development also bode well for future profitability and potential acquisitions.

Bears say

Teva Pharmaceutical Indus is facing significant challenges in the near future due to increasing competition in the generic drug market, potential loss of patent exclusivity for its leading drug Copaxone, and ongoing litigation and settlements related to opioid lawsuits. This, combined with its high debt levels and declining revenues, suggests a negative outlook for the company's financial performance in the coming years. Additionally, Teva's recent acquisition of businesses further adds to its debt burden and may hinder its ability to invest in research and development for innovative drugs. These factors could lead to a decline in Teva's market share and overall profitability.

Teva Pharmaceutical (TEVA) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teva Pharmaceutical (TEVA) Forecast

Analysts have given Teva Pharmaceutical (TEVA) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Teva Pharmaceutical (TEVA) has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teva Pharmaceutical (TEVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.